Introducing Proscia Aperture: Real-time Patient Insights at the Point of DiagnosisGET ACCESS

One platform. Three purpose-built products.

Concentriq LS

From biomarker discovery to clinical trials, life sciences leaders rely on Concentriq LS to fast-track breakthroughs and turn siloed pathology data into a competitive advantage.

ACCELERATE YOUR R&D

Concentriq AP

Leading academic medical centers, health systems, and commercial labs leverage Concentriq AP’s advanced digitization and AI to go fully digital — and never look back.

DIGITIZE YOUR LAB

Concentriq AP-Dx

FDA-cleared for primary diagnosis, Concentriq AP-Dx offers an intuitive experience for interpreting and managing cases, advancing both late-stage clinical trials and diagnostic workflows.

MODERNIZE DIAGNOSIS

Concentriq is the most trusted enterprise digital pathology platform. Find out why.

Schedule a Demo

Explore our solutions from discovery to diagnosis

Laboratory operations manager using Concentriq® for Research

Discover, develop, deliver — faster

Deploy Concentriq, Proscia Aperture, and AI across the R&D lifecycle to bring treatments to market faster and reach more patients worldwide.

Solutions For Life Sciences

Pathlogist using Concentriq®

Run a modern, more productive lab

Accelerate your shift to 100% digital diagnosis — improve diagnostic quality, increase efficiency, and position your lab for future growth.

Solutions For Diagnostics

Accelerate precision medicine with AI

From development tools to analysis applications, scientists and pathologists can build and deploy AI solutions that accelerate therapy development and deliver precision diagnostics.

AI PORTFOLIO

Proscia Aperture™

Access real-time, point-of-diagnosis patient insights

Proscia Aperture is a precision medicine solution that turns data into insight at the moment of diagnosis. Accelerate drug development and generate real-world evidence for market access strategies.

ACCESS APERTURE

Visionaries trust our vision

Leaders like PathGroup partner with us to help them rewire pathology for precision medicine. They know that our approach to digital pathology and AI is the key to smart, scalable growth and better patient care.

“With Proscia, we are going 100% digital to accelerate growth, improve our pathologist experience, and open new data opportunities with leading pharmas and CROs.”

Dr. Derek Welch, MD, FCAP, Chief Medical Officer, PathGroup

FIND OUT WHY

More than 12,000 pathologists and scientists use our platform daily at diagnostic laboratories and life sciences organizations, including major CROs and 16 of the top 20 pharma leaders.

Proscia Leads The Way Forward in Digital Pathology

We’re proud to be recognized for these outstanding achievements as we advance our mission to change the way we fight diseases like cancer.

Fast-Company - Next Big Things In Tech 2024

Fierce Biotech Fierce 15

KLAS Research - Emerging Solutions Top 20

Latest News & Events

Virtual Event

Access25: Precision Medicine Starts at the Moment of Diagnosis

October 28, 2025 | 11:30AM ET

Join Access25 to discover how Proscia is removing one of the biggest barriers to realizing precision medicine — access to the right patients, at the right moment, with the right data. Get a first look at Proscia Aperture and discover how real-time access to patient insights benefits both biopharma R&D and clinical labs. A Partner Expo will feature breakthroughs in pathology AI, next-generation infrastructure, and enterprise solutions—delivered by the strongest ecosystem in the industry.

JOIN ACCESS25Link Arrow

Webinar

Survey Insights on Pathology’s Transformation to AI and Precision Medicine from Laboratory Leadership

Aired July 16, 2025 | Watch On Demand

Watch a panel discussion about the state of digital pathology and AI with Proscia customers PathGroup, Cleveland Clinic, and Spectrum Healthcare Partners. Leaders from these innovative and forward-thinking laboratories discuss findings from a recent survey of 360+ laboratory professionals.

WATCH ON-DEMANDLink Arrow

Our website uses cookies. By using this site, you agree to its use of cookies.